Compare INDV & SHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDV | SHC |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.4B |
| IPO Year | 2014 | 2020 |
| Metric | INDV | SHC |
|---|---|---|
| Price | $31.49 | $15.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $20.67 |
| AVG Volume (30 Days) | 2.3M | ★ 2.6M |
| Earning Date | 06-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8100.00 | 68.75 |
| EPS | ★ 1.64 | 0.27 |
| Revenue | ★ $1,239,000,000.00 | $1,163,617,000.00 |
| Revenue This Year | N/A | $7.51 |
| Revenue Next Year | N/A | $6.00 |
| P/E Ratio | ★ $19.28 | $58.22 |
| Revenue Growth | 4.29 | ★ 5.74 |
| 52 Week Low | $8.69 | $10.17 |
| 52 Week High | $38.00 | $19.85 |
| Indicator | INDV | SHC |
|---|---|---|
| Relative Strength Index (RSI) | 52.09 | 62.66 |
| Support Level | $29.71 | $15.19 |
| Resistance Level | $35.75 | $16.55 |
| Average True Range (ATR) | 1.20 | 0.44 |
| MACD | 0.30 | 0.31 |
| Stochastic Oscillator | 74.90 | 99.25 |
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.